mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2026-2-7-12mrj-1951Research ArticleЛЕКЦИЯLECTUREЛабораторные биомаркеры поражения сердца при системной склеродермии. Часть 1Laboratory biomarkers of cardiac involvement in systemic sclerosis. Part 1https://orcid.org/0000-0002-5012-0540ГарзановаЛ. А.GarzanovaL. A.

Людмила Александровна Гарзанова 

Москва, 115522, Москва, Каширское шоссе, 34А 

Lyudmila Aleksandrovna Garzanova 

34A, Kashirskoe Shosse, Moscow115522 

lyuda-garzanova@yandex.ruhttps://orcid.org/0000-0002-3248-6426АнаньеваЛ. П.AnanyevaL. P.

Москва, 115522, Москва, Каширское шоссе, 34А 

34A, Kashirskoe Shosse, Moscow115522 

https://orcid.org/0000-0003-3650-7658КоневаО. А.KonevaO. A.

Москва, 115522, Москва, Каширское шоссе, 34А 

34A, Kashirskoe Shosse, Moscow115522 

https://orcid.org/0000-0003-2667-4284ОвсянниковаО. Б.OvsyannikovaO. B.

Москва, 115522, Москва, Каширское шоссе, 34А 

34A, Kashirskoe Shosse, Moscow115522 

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202622042026202712Copyright © Гарзанова Л.А., Ананьева Л.П., Конева О.А., Овсянникова О.Б., 20262026Гарзанова Л.А., Ананьева Л.П., Конева О.А., Овсянникова О.Б.Garzanova L.A., Ananyeva L.P., Koneva O.A., Ovsyannikova O.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1951

Поражение сердца – одно из тяжелых проявлений системной склеродермии (ССД), которое варьируется от субклинических форм до опасных для жизни состояний, характеризуется плохим прогнозом и высокой смертностью. Кардиопатия при ССД может быть первичной и вторичной, связанной с сопутствующими заболеваниями. Поэтому важную роль играет своевременная диагностика первичного поражения сердца, в частности определение сывороточных биомаркеров.В обзоре рассмотрены варианты лабораторных биомаркеров для выявления первичного поражения сердца при ССД, их вклад в раннюю диагностику и прогнозирование течения заболевания.

Cardiac involvement is one of the severe manifestations of systemic sclerosis (SSc), ranging from subclinical forms to life-threatening conditions, and is characterized by poor prognosis and high mortality. Cardiopathy in SSc may be primary or secondary, associated with comorbid conditions. Therefore, timely diagnosis of primary cardiac involvement is of particular importance, including the assessment of serum biomarkers.This review discusses laboratory biomarkers for the detection of primary cardiac involvement in SSc, their role in early diagnosis, and their value in predicting disease course.

системная склеродермияпоражение сердцабиомаркерыsystemic sclerosiscardiac involvementbiomarkersСтатья подготовлена в рамках фундаментальной научной темы РК 125020501434-1.The article was prepared within the framework of the basic scientific research project RK 125020501434-1.ReferencesVolkmann ER, Andreasson K, Smith V. Systemic sclerosis. Lancet. 2023 Jan 28; 401(10373):304-318. doi: 10.1016/S0140-6736(22)01692-0.Volkmann ER, Andreasson K, Smith V. Systemic sclerosis. Lancet. 2023 Jan 28; 401(10373):304-318. doi: 10.1016/S0140-6736(22)01692-0.Bournia VK, Tountas C, Protogerou AD, et al. Update on assessment and management of primary cardiac involvement in systemic sclerosis. J Scleroderma Relat Disord. 2018 Feb;3(1):53-65. doi: 10.1177/2397198317747441.Bournia VK, Tountas C, Protogerou AD, et al. Update on assessment and management of primary cardiac involvement in systemic sclerosis. J Scleroderma Relat Disord. 2018 Feb;3(1):53-65. doi: 10.1177/2397198317747441.Moore DF, Steen VD. Overall mortality. J Scleroderma Relat Disord. 2021 Feb;6(1): 3-10. doi: 10.1177/2397198320924873.Moore DF, Steen VD. Overall mortality. J Scleroderma Relat Disord. 2021 Feb;6(1): 3-10. doi: 10.1177/2397198320924873.Guedon AF, Carrat F, Mouthon L, et al. Heart and systemic sclerosis-findings from a national cohort study. Rheumatology (Oxford). 2024 Dec 1;63(12):3380-3389. doi: 10.1093/rheumatology/kead599.Guedon AF, Carrat F, Mouthon L, et al. Heart and systemic sclerosis-findings from a national cohort study. Rheumatology (Oxford). 2024 Dec 1;63(12):3380-3389. doi: 10.1093/rheumatology/kead599.Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017 Nov; 76(11):1897-1905. doi: 10.1136/annrheumdis-2017-211448.Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017 Nov; 76(11):1897-1905. doi: 10.1136/annrheumdis-2017-211448.Pinter T, Faludi R, Magyari B, et al. Mechanism of coronary flow reserve reduction in systemic sclerosis: insight from intracoronary pressure wire studies. Rheumatology (Oxford). 2011 Apr;50(4):781-8. doi: 10.1093/rheumatology/keq402.Pinter T, Faludi R, Magyari B, et al. Mechanism of coronary flow reserve reduction in systemic sclerosis: insight from intracoronary pressure wire studies. Rheumatology (Oxford). 2011 Apr;50(4):781-8. doi: 10.1093/rheumatology/keq402.Kahan A, Coghlan G, McLaughlin V. Cardiac complications of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3: iii45-8. doi: 10.1093/rheumatology/kep110.Kahan A, Coghlan G, McLaughlin V. Cardiac complications of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3: iii45-8. doi: 10.1093/rheumatology/kep110.Bruni C, Ross L. Cardiac involvement in systemic sclerosis: Getting to the heart of the matter. Best Pract Res Clin Rheumatol. 2021 Sep;35(3):101668. doi: 10.1016/j.berh.2021.101668.Bruni C, Ross L. Cardiac involvement in systemic sclerosis: Getting to the heart of the matter. Best Pract Res Clin Rheumatol. 2021 Sep;35(3):101668. doi: 10.1016/j.berh.2021.101668.Bruni C, Buch MH, Furst DE, et al. Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. J Scleroderma Relat Disord. 2022 Feb; 7(1):24-32. doi: 10.1177/23971983211053246.Bruni C, Buch MH, Furst DE, et al. Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. J Scleroderma Relat Disord. 2022 Feb; 7(1):24-32. doi: 10.1177/23971983211053246.Wermuth PJ, Piera-Velazquez S, Rosenbloom J, Jimenez SA. Existing and novel biomarkers for precision medicine in systemic sclerosis. Nat Rev Rheumatol. 2018 Jul; 14(7):421-432. doi: 10.1038/s41584-018-0021-9.Wermuth PJ, Piera-Velazquez S, Rosenbloom J, Jimenez SA. Existing and novel biomarkers for precision medicine in systemic sclerosis. Nat Rev Rheumatol. 2018 Jul; 14(7):421-432. doi: 10.1038/s41584-018-0021-9.Leclair V, D'Aoust J, Gyger G, et al. Canadian Inflammatory Myopathy Study Group. Autoantibody profiles delineate distinct subsets of scleromyositis. Rheumatology (Oxford). 2022 Mar;61(3):1148-1157. doi: 10.1093/rheumatology/keab492.Leclair V, D'Aoust J, Gyger G, et al. Canadian Inflammatory Myopathy Study Group. Autoantibody profiles delineate distinct subsets of scleromyositis. Rheumatology (Oxford). 2022 Mar;61(3):1148-1157. doi: 10.1093/rheumatology/keab492.Ананьева ЛП, Александрова ЕН Аутоантитела при системной склеродермии: спектр, клинические ассоциации и прогностическое значение. Научно-практическая ревматология. 2016;54(1):86-99.Ananyeva LP, Aleksandrova EN. Autoantibodies in systemic sclerosis: spectrum, clinical associations, and prognostic value. Nauchnoprakticheskaya revmatologiya. 2016;54(1): 86-99. (In Russ.).van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov; 72(11):1747-55. doi: 10.1136/annrheumdis-2013-204424.van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov; 72(11):1747-55. doi: 10.1136/annrheumdis-2013-204424.Cavazzana I, Vojinovic T, Airo' P, et al. Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers. Clin Rev Allergy Immunol. 2023 Jun;64(3):412-430. doi: 10.1007/s12016-022-08946-w.Cavazzana I, Vojinovic T, Airo' P, et al. Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers. Clin Rev Allergy Immunol. 2023 Jun;64(3):412-430. doi: 10.1007/s12016-022-08946-w.Mahler M, Hudson M, Bentow C, et al. Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets. Autoimmun Rev. 2020 Aug;19(8):102583. doi: 10.1016/j.autrev.2020.102583.Mahler M, Hudson M, Bentow C, et al. Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets. Autoimmun Rev. 2020 Aug;19(8):102583. doi: 10.1016/j.autrev.2020.102583.Nihtyanova SI, Sari A, Harvey JC, et al. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis. Arthritis Rheumatol. 2020 Mar;72(3):465-476. doi: 10.1002/art.41153.Nihtyanova SI, Sari A, Harvey JC, et al. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis. Arthritis Rheumatol. 2020 Mar;72(3):465-476. doi: 10.1002/art.41153.Aggarwal R, Lucas M, Fertig N, et al. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum. 2009 Apr;60(4): 1112-8. doi: 10.1002/art.24409.Aggarwal R, Lucas M, Fertig N, et al. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum. 2009 Apr;60(4): 1112-8. doi: 10.1002/art.24409.Tormey VJ, Bunn CC, Denton CP, Black CM. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford). 2001 Oct;40(10):1157-62. doi: 10.1093/rheumatology/40.10.1157.Tormey VJ, Bunn CC, Denton CP, Black CM. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford). 2001 Oct;40(10):1157-62. doi: 10.1093/rheumatology/40.10.1157.Keppeke GD, Satoh M, Kayser C, et al. A cell-based assay for detection of anti-fibrillarin autoantibodies with performance equivalent to immunoprecipitation. Front Immunol. 2022 Sep;13:1011110. doi: 10.3389/fimmu.2022.1011110.Keppeke GD, Satoh M, Kayser C, et al. A cell-based assay for detection of anti-fibrillarin autoantibodies with performance equivalent to immunoprecipitation. Front Immunol. 2022 Sep;13:1011110. doi: 10.3389/fimmu.2022.1011110.Kaji K, Fertig N, Medsger TA Jr, et al. Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res (Hoboken). 2014 Apr;66(4):575-84. doi: 10.1002/acr.22163.Kaji K, Fertig N, Medsger TA Jr, et al. Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res (Hoboken). 2014 Apr;66(4):575-84. doi: 10.1002/acr.22163.Pauling JD, Salazar G, Hui Lu, et al. Presence of anti-eukaryotic initiation factor- 2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis. Rheumatology (Oxford). 2018 Apr;57(4):712-717. doi: 10.1093/rheumatology/kex458.Pauling JD, Salazar G, Hui Lu, et al. Presence of anti-eukaryotic initiation factor- 2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis. Rheumatology (Oxford). 2018 Apr;57(4):712-717. doi: 10.1093/rheumatology/kex458.Di Pietro L, Chiccoli F, Salvati L, et al. Anti-RuvBL1/2 Autoantibodies Detection in a Patient with Overlap Systemic Sclerosis and Polymyositis. Antibodies (Basel). 2023 Feb; 12(1):13. doi: 10.3390/antib12010013.Di Pietro L, Chiccoli F, Salvati L, et al. Anti-RuvBL1/2 Autoantibodies Detection in a Patient with Overlap Systemic Sclerosis and Polymyositis. Antibodies (Basel). 2023 Feb; 12(1):13. doi: 10.3390/antib12010013.Caforio AL, Tona F, Bottaro S, et al. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity. 2008 Feb;41(1):35-45. doi: 10.1080/08916930701619235.Caforio AL, Tona F, Bottaro S, et al. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity. 2008 Feb;41(1):35-45. doi: 10.1080/08916930701619235.Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013 Sep;34(33):2636-48, 2648a- 2648d. doi: 10.1093/eurheartj/eht210.Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013 Sep;34(33):2636-48, 2648a- 2648d. doi: 10.1093/eurheartj/eht210.Caforio AL, Calabrese F, Angelini A, et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J. 2007 Jun;28(11):1326-33. doi: 10.1093/eurheartj/ehm076.Caforio AL, Calabrese F, Angelini A, et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J. 2007 Jun;28(11):1326-33. doi: 10.1093/eurheartj/ehm076.Peretto G, Sala S, De Luca G, et al. Immunosuppressive Therapy and Risk Stratification of Patients With Myocarditis Presenting With Ventricular Arrhythmias. JACC Clin Electrophysiol. 2020 Oct;6(10):1221-1234. doi: 10.1016/j.jacep.2020.05.013.Peretto G, Sala S, De Luca G, et al. Immunosuppressive Therapy and Risk Stratification of Patients With Myocarditis Presenting With Ventricular Arrhythmias. JACC Clin Electrophysiol. 2020 Oct;6(10):1221-1234. doi: 10.1016/j.jacep.2020.05.013.Blagova O, Varionchik N, Zaidenov V, et al. Anti-heart antibodies levels and their correlation with clinical symptoms and outcomes in patients with confirmed or suspected diagnosis COVID-19. Eur J Immunol. 2021 Apr;51(4):893-902. doi: 10.1002/eji.202048930.Blagova O, Varionchik N, Zaidenov V, et al. Anti-heart antibodies levels and their correlation with clinical symptoms and outcomes in patients with confirmed or suspected diagnosis COVID-19. Eur J Immunol. 2021 Apr;51(4):893-902. doi: 10.1002/eji.202048930.Caforio ALP, De Luca G, Baritussio A, et al. Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates. Diagnotics (Basel). 2021 Nov;11(11):2165. doi: 10.3390/diagnostics11112165.Caforio ALP, De Luca G, Baritussio A, et al. Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates. Diagnotics (Basel). 2021 Nov;11(11):2165. doi: 10.3390/diagnostics11112165.Lewis RA, Durrington C, Condliffe R, Kiely DG. BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing? Eur Respir Rev. 2020 May;29(156): 200009. doi: 10.1183/16000617.0009-2020.Lewis RA, Durrington C, Condliffe R, Kiely DG. BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing? Eur Respir Rev. 2020 May;29(156): 200009. doi: 10.1183/16000617.0009-2020.Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A. 2000 Apr;97(8):4239-44. doi: 10.1073/pnas.070371497.Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A. 2000 Apr;97(8):4239-44. doi: 10.1073/pnas.070371497.Thakkar V, Stevens WM, Prior D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a casecontrol study. Arthritis Res Ther. 2012 Jun; 14(3):R143. doi: 10.1186/ar3876.Thakkar V, Stevens WM, Prior D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a casecontrol study. Arthritis Res Ther. 2012 Jun; 14(3):R143. doi: 10.1186/ar3876.Ross L, Moxey J, Nikpour M. Are troponin and B-type natriuretic peptides useful biomarkers for the diagnosis of systemic sclerosis heart involvement? A systematic literature review. Semin Arthritis Rheum. 2021 Feb; 51(1):299-309. doi: 10.1016/j.semarthrit.2020.10.016.Ross L, Moxey J, Nikpour M. Are troponin and B-type natriuretic peptides useful biomarkers for the diagnosis of systemic sclerosis heart involvement? A systematic literature review. Semin Arthritis Rheum. 2021 Feb; 51(1):299-309. doi: 10.1016/j.semarthrit.2020.10.016.Bosello S, De Luca G, Berardi G, et al. Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. Eur J Intern Med. 2019 Feb;60:46-53. doi: 10.1016/j.ejim.2018.10.013.Bosello S, De Luca G, Berardi G, et al. Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. Eur J Intern Med. 2019 Feb;60:46-53. doi: 10.1016/j.ejim.2018.10.013.Ciurzynski M, Bienias P, Irzyk K, et al. Serum endothelin-1 and NT-proBNP, but not ADMA, endoglin and TIMP-1 levels, reflect impaired right ventricular function in patients with systemic sclerosis. Clin Rheumatol. 2014 Jan;33(1):83-9. doi: 10.1007/s10067-013-2354-8.Ciurzynski M, Bienias P, Irzyk K, et al. Serum endothelin-1 and NT-proBNP, but not ADMA, endoglin and TIMP-1 levels, reflect impaired right ventricular function in patients with systemic sclerosis. Clin Rheumatol. 2014 Jan;33(1):83-9. doi: 10.1007/s10067-013-2354-8.Chighizola C, Meroni PL, Schreiber BE, et al. Role of N-terminal pro-brain natriuretic peptide in detecting clinically significant cardiac involvement in systemic sclerosis patients. Clin Exp Rheumatol. 2012 Mar-Apr; 30(2 Suppl 71):S81-5.Chighizola C, Meroni PL, Schreiber BE, et al. Role of N-terminal pro-brain natriuretic peptide in detecting clinically significant cardiac involvement in systemic sclerosis patients. Clin Exp Rheumatol. 2012 Mar-Apr; 30(2 Suppl 71):S81-5.Allanore Y, Komocsi A, Vettori S, et al. N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis. Int J Cardiol. 2016 Nov;223:385-389. doi: 10.1016/j.ijcard.2016.08.246.Allanore Y, Komocsi A, Vettori S, et al. N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis. Int J Cardiol. 2016 Nov;223:385-389. doi: 10.1016/j.ijcard.2016.08.246.Dumitru RB, Bissell LA, Erhayiem B, et al. Cardiovascular outcomes in systemic sclerosis with abnormal cardiovascular MRI and serum cardiac biomarkers. RMD Open. 2021 Oct;7(3):e001689. doi: 10.1136/rmdopen-2021-001689.Dumitru RB, Bissell LA, Erhayiem B, et al. Cardiovascular outcomes in systemic sclerosis with abnormal cardiovascular MRI and serum cardiac biomarkers. RMD Open. 2021 Oct;7(3):e001689. doi: 10.1136/rmdopen-2021-001689.Bissell LA, Anderson M, Burgess M, et al. Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. Rheumatology (Oxford). 2017 Jun;56(6):912- 921. doi: 10.1093/rheumatology/kew488.Bissell LA, Anderson M, Burgess M, et al. Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. Rheumatology (Oxford). 2017 Jun;56(6):912- 921. doi: 10.1093/rheumatology/kew488.Alehagen U, Dahlström U, Lindahl TL. Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur J Heart Fail. 2009 Apr; 11(4):354-60. doi: 10.1093/eurjhf/hfp024.Alehagen U, Dahlström U, Lindahl TL. Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur J Heart Fail. 2009 Apr; 11(4):354-60. doi: 10.1093/eurjhf/hfp024.Patel PC, Ayers CR, Murphy SA, et al. Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail. 2009 Mar;2(2):98-104. doi: 10.1161/CIRCHEARTFAILURE.108.807271.Patel PC, Ayers CR, Murphy SA, et al. Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail. 2009 Mar;2(2):98-104. doi: 10.1161/CIRCHEARTFAILURE.108.807271.Filler G, Bökenkamp A, Hofmann W, et al. Cystatin C as a marker of GFR – history, indications, and future research. Clin Biochem. 2005 Jan;38(1):1-8. doi: 10.1016/j.clinbiochem.2004.09.025.Filler G, Bökenkamp A, Hofmann W, et al. Cystatin C as a marker of GFR – history, indications, and future research. Clin Biochem. 2005 Jan;38(1):1-8. doi: 10.1016/j.clinbiochem.2004.09.025.Krusche M, Osei-Davies R, Becker I, et al. Renal Function in Patients With Systemic Sclerosis: Do We Estimate It Correctly? J Clin Rheumatol. 2022 Mar;28(2):e642-e646. doi: 10.1097/RHU.0000000000001791.Krusche M, Osei-Davies R, Becker I, et al. Renal Function in Patients With Systemic Sclerosis: Do We Estimate It Correctly? J Clin Rheumatol. 2022 Mar;28(2):e642-e646. doi: 10.1097/RHU.0000000000001791.Siegert E, March C, Otten L, et al. Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis. Nutrition. 2018 Nov;55-56:51-55. doi: 10.1016/j.nut.2018.03.046.Siegert E, March C, Otten L, et al. Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis. Nutrition. 2018 Nov;55-56:51-55. doi: 10.1016/j.nut.2018.03.046.Akkus O, Bozkurt A, Arslantas D, et al. Is cystatin C an evaluative marker for right heart functions in systemic sclerosis? Int J Cardiol. 2016 Oct;221:478-83. doi: 10.1016/j.ijcard.2016.07.093.Akkus O, Bozkurt A, Arslantas D, et al. Is cystatin C an evaluative marker for right heart functions in systemic sclerosis? Int J Cardiol. 2016 Oct;221:478-83. doi: 10.1016/j.ijcard.2016.07.093.Jha M, Wang M, Steele R, et al. NT-proBNP, hs-cTnT, and CRP predict the risk of cardiopulmonary outcomes in systemic sclerosis: Findings from the Canadian Scleroderma Research Group. J Scleroderma Relat Disord. 2022 Feb;7(1):62-70. doi: 10.1177/23971983211040608.Jha M, Wang M, Steele R, et al. NT-proBNP, hs-cTnT, and CRP predict the risk of cardiopulmonary outcomes in systemic sclerosis: Findings from the Canadian Scleroderma Research Group. J Scleroderma Relat Disord. 2022 Feb;7(1):62-70. doi: 10.1177/23971983211040608.Barsotti S, Stagnaro C, d'Ascanio A, et al. High sensitivity troponin might be a marker of subclinical scleroderma heart involvement: a preliminary study. J Scleroderma Relat Disord. 2017 July;2(3):183-187. doi: 10.5301/jsrd.5000244Barsotti S, Stagnaro C, d'Ascanio A, et al. High sensitivity troponin might be a marker of subclinical scleroderma heart involvement: a preliminary study. J Scleroderma Relat Disord. 2017 July;2(3):183-187. doi: 10.5301/jsrd.5000244

The authors declare that there are no conflicts of interest present.